Program
DA-1229_01
Its studies are mostly in Diabetes Mellitus, Type 2, led by Dong-A ST.
Furthest: phase 1, since Jun 11, 20144 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dong-A ST | 40 open or running | phase 1since Jun 11, 2014 | Jun 11, 2014 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 11, 2014First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT02167061 · 64 enrolled · Korea, Republic of
- Feb 24, 2015Phase 1 study in Diabetes Mellitus, Type 2NCT02375139 · 36 enrolled · Korea, Republic of
- Dec 9, 2025Phase 1 study in HealthyNCT07297940 · 42 enrolled · South Korea
- Jan 6, 2026Phase 1 study in HealthyNCT07342062 · 36 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07342062Healthy · South Korea | 1 | Completed | Feb 14, 2026 | 36 |
| NCT07297940Healthy · South Korea | 1 | Completed | Jan 31, 2026 | 42 |
| NCT02375139Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Jun 2015 | 36 |
| NCT02167061Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Nov 2014 | 64 |
How it is read
Names in the registry
- “DA-1229_01”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.